Soleno Therapeutics, Inc. (SLNO)
| Market Cap | 2.76B -19.9% |
| Revenue (ttm) | 285.01M |
| Net Income | 95.63M |
| EPS | 1.77 |
| Shares Out | 52.12M |
| PE Ratio | 30.00 |
| Forward PE | 11.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,968,834 |
| Open | 52.99 |
| Previous Close | n/a |
| Day's Range | 52.98 - 53.01 |
| 52-Week Range | 29.43 - 90.32 |
| Beta | -2.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About SLNO
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsid... [Read more]
Financial Performance
Financial StatementsNews
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
Folia Health's fully remote, app-based study sponsored by Soleno Therapeutics follows PWS caregivers over six months to capture their daily experiences.
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)? Did you purchase your shares between March 26, 2025 and...
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
Soleno Therapeutics said on Tuesday it has voluntarily withdrawn the European marketing application for its rare metabolic disorder drug following acquirer Neurocrine's plans to sharpen focus on the...
Neurocrine to Buy Soleno for $2.9 Billion
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion in a move intended to expand its endocrinology and rare-disease portfolio.
Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday.
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercia...
SLNO Stockholders Have Rights – If You Lost Money Investing in Soleno Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Robbins LLP is Investigating Allegations that Soleno Therapeutics SLNO Misled Investors Regarding the Viability and Efficacy of its Phase 3 Clinical Trial
Soleno Therapeutics Slides: Corporate presentation
Soleno Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 18, 2026.
Notice to Long-Term Investors of Soleno Therapeutics, Inc. (SLNO): Grabar Law Office Investigates Claims on Your Behalf
Philadelphia, Pennsylvania--(Newsfile Corp. - March 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SL...
SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt
Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug Safety NEW YORK, March 12, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutic...
Soleno Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
VYKAT XR's launch has exceeded expectations with strong revenue, broad payer coverage, and high prescriber engagement. Expansion into new indications and international markets is underway, with a focus on education and community partnerships to drive growth.
Soleno Therapeutics Earnings Call Transcript: Q4 2025
VYKAT XR's launch drove $190.4M in 2025 revenue and profitability, with 1,250 patient start forms and 859 active patients. EU approval for DCCR is expected mid-2026, and expansion into GSD I is planned. Strong cash reserves support ongoing growth.
Soleno Therapeutics Annual report: Q4 2025
Soleno Therapeutics has published its Q4 2025 annual report on February 25, 2026.
Soleno Therapeutics Earnings release: Q4 2025
Soleno Therapeutics released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Soleno Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Achieved 10% market penetration with strong prescriber adoption and stable discontinuation rates. Revenue growth is driven by active patient build and favorable reimbursement, while international expansion and new indications are key strategic priorities.
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors vi...
Soleno Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
VYKAT XR's launch has captured 10% of the TAM in six months, with strong market access and broad prescriber engagement. Education initiatives and support programs are driving ongoing uptake, while safety and regulatory profiles remain consistent with expectations.
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...
Soleno Therapeutics Transcript: Jefferies London Healthcare Conference 2025
VYKAT XR, the first FDA-approved treatment for Prader-Willi syndrome, has seen rapid adoption, robust reimbursement, and strong financial performance. Clinical data confirm significant efficacy and manageable safety, with European expansion and patent protection through 2035.
Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., (“Soleno" or the "Company") (NASDAQ: SLNO) investors that the firm has initiated an investigation...
Soleno Therapeutics Transcript: Stifel 2025 Healthcare Conference
Q3 saw doubled revenue, profitability, and strong patient access, with 10% of the addressable market reached in six months. Patient growth is expected to continue, supported by robust payer coverage and positive real-world efficacy and safety. EU expansion is progressing, with a decision on partnering or self-launch pending.
Soleno Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Revenues doubled to $66 million with strong cash flow and 10% market penetration in six months. Physician education and peer programs are expanding adoption, while a $100 million buyback signals confidence. European launch is on track for Q2, with regulatory progress and initial focus on Germany.